Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Kidney Int. 2018 Oct 6;94(6):1151–1159. doi: 10.1016/j.kint.2018.06.031

Figure 5. Hydroxypropyl-β–Cyclodextrin (HPβCD) improves renal function in Adriamycin (ADR) injected mice.

Figure 5.

Four groups of BALB/c female mice (n=6 per group) were utilized: 1) Control (CTRL); 2) ADR, mice injected with a single dose of ADR (11 mg/kg); 3) CD, mice receiving only HPβCD subcutaneously (40 mg/kg); 4) ADR+CD, mice receiving HPβCD subcutaneously (40 mg/kg) after a single dose of ADR (11 mg/kg). All data are presented as mean ± SD. (A) HPβCD administration after a single dose of ADR results in a significant reduction in the albumin/creatinine ratio (ACR) 10 weeks after initiation of the treatment compared to untreated mice (CTRL). **p<0.01, One-Way ANOVA. (B) Bar graph analysis showing significantly increased serum BUN levels in ADR mice compared to controls. Treatment with HPβCD results in a significant reduction of serum BUN levels in the ADR+CD group compared to ADR group. *p<0.05; **p<0.01, One-Way ANOVA. (C) Serum creatinine did not increase in ADR-treated mice and was not affected by HPβCD. (D) Representative Periodic Acid-Schiff staining of kidney sections (4 μm) from CTRL, ADR, CD and ADR+CD mice after 10 weeks of treatment with HPβCD (40x). Bars are 20μm. (E) Bar graph analysis of the mesangial expansion scored by two blinded, independent investigators in PAS-stained kidney sections after 10 weeks of treatment with HPβCD. Treatment with HPβCD protects ADR injected mice from mesangial expansion. *p<0.05, ***p<0.001, One-Way ANOVA.